Blood-Derived Processing Service "PDF-FD" Adopted by National Hospital for the First Time!

Waqoo Co., Ltd. (President and Representative Director: Bumpei Samata) is pleased to announce that our blood-derived processing service, "PDF-FD," has been officially adopted by the Department of Orthopedic Surgery at the National Hospital Organization Sagamihara Hospital (hereinafter referred to as "Sagamihara Hospital"). This is the first time our service has been adopted by a national hospital.

Sagamihara Hospital operates under the philosophy: "We respect the human rights of our patients and provide kind, heartfelt medical care based on sufficient explanation and consent." As an acute care general hospital with roots in the former Imperial Army and national hospitals, it is the oldest public hospital in the Sagamihara region.

Our company, which provides contract services for blood-derived processing, and our subsidiary, Cell Pro Japan Co., Ltd., which possesses the manufacturing technology, will continue to work together as a group to provide safer services to Sagamihara Hospital. We will also maintain close cooperation with Sagamihara Hospital to contribute to the development of orthopedic treatment.

National Hospital Organization Sagamihara Hospital

Location: 18-1 Sakuradai, Minami-ku, Sagamihara-shi, Kanagawa 252-0392 Hospital Director: Ken Adachi Date of Establishment: April 1, 1938 (Established as an Independent Administrative Institution on April 1, 2004) Number of Authorized Beds: 458 general beds (including 4 HCU beds) Website: https://sagamihara.hosp.go.jp/index.html

About Waqoo Co., Ltd. and Cell Pro Japan Co., Ltd.

[Waqoo Co., Ltd.] Website: https://waqoo.jp/ Location: 2-14-1 Kamiuma, Setagaya-ku, Tokyo Representative: Bumpei Samata, President and Representative Director

Under the mission of "Creating hope for our country's future" and the vision of "Maximizing the potential of cells = humanity (people) and providing options for those who are suffering," the company focuses on its medical support business, which includes contract processing services for "blood-derived PDF-FD" and the sale of cosmetic raw materials. It also develops and plans original cosmetic brands utilizing digital marketing. Moving forward, the company aims to provide products and services that exceed customer expectations in the field of regenerative medicine.

[Cell Pro Japan Co., Ltd.] Website: https://cellprojapan.com/ Location: Shonan Health Innovation Park, 2-26-1 Muraoka-higashi, Fujisawa-shi, Kanagawa Representative: Bumpei Samata, President and Representative Director

A bio-venture company founded by active researchers involved in cutting-edge stem cell research in academia. Leveraging expertise in stem cell research, the company conducts research and development of products and raw materials to contribute to the spread and development of regenerative medicine. It possesses development technology for human stem cell-derived culture supernatant and realizes the provision of high-quality, highly safe services through thorough donor screening, manufacturing management, and inspection systems.